Literature DB >> 9041320

Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a.

K Yoshioka1, T Aiyama, A Okumura, M Takayanagi, K Iwata, T Ishikawa, Y Nagai, S Kakumu.   

Abstract

Antibody to the hypervariable region (HVR) of HCV is thought to have neutralizing activity. The HCV genotype is known to affect the clinical course of infection. The antibody response to HVR and its relationship to the virologic and clinical characteristics were investigated in 21 patients with chronic hepatitis C. HVRs amplified by polymerase chain reaction from serum HCV were expressed as glutathione S-transferase fusion proteins. From 8 to 34 clones per serum sample were obtained (375 clones total), and the anti-HVR antibody in serum was assessed by Western blot. Both the incidence of fusion proteins positive for anti-HVR antibody and the activity of antibody were significantly higher in 6 patients with genotype 2a than in 15 patients with genotype 1b. This result suggests that the quantity of humoral response to HVR affects the clinical outcome of infection with these two HCV genotypes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041320     DOI: 10.1093/infdis/175.3.505

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome.

Authors:  Gianguglielmo Zehender; Chiara De Maddalena; Flavia Bernini; Erika Ebranati; Giuseppe Monti; Piero Pioltelli; Massimo Galli
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors:  K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Local immunodeficiency: Minimal networks and stability.

Authors:  Leonid Bunimovich; Longmei Shu
Journal:  Math Biosci       Date:  2019-02-14       Impact factor: 2.144

5.  Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.

Authors:  Pavel Skums; Leonid Bunimovich; Yury Khudyakov
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

6.  How Escherichia coli can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure.

Authors:  X Forns; J Bukh; R H Purcell; S U Emerson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

7.  Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls.

Authors:  Gabriella Bianchettin; Claudia Bonaccini; Romina Oliva; Anna Tramontano; Agostino Cividini; Milvia Casato; Giampaolo Merlini; Enrico Silini; Mario U Mondelli
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

Review 8.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

9.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

10.  Hepatitis C virus antigenic convergence.

Authors:  David S Campo; Zoya Dimitrova; Jonny Yokosawa; Duc Hoang; Nestor O Perez; Sumathi Ramachandran; Yury Khudyakov
Journal:  Sci Rep       Date:  2012-02-15       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.